Mitogen-Activated Protein Kinase (MAPK) Signaling

  • Andrei Zlobin
  • Jeffrey C. Bloodworth
  • Clodia OsipoEmail author


The mitogen-activated protein kinases (MAPKs) have been under careful investigation for a long period, and this signaling pathway is one of the most studied. MAPKs regulate cell proliferation, gene expression, differentiation, mitosis, cell survival, and apoptosis. The mitogen-activated protein/extracellular signal-regulated kinase (MAPK/ERK) pathways are a cascade of signaling enzymes starting with the transmission of a signal from a receptor tyrosine kinase (RTK) located on the cell surface to the nucleus and ending in the regulation of transcription of target genes. Due to its importance in human cancers, MAPK/ERK signaling pathways are attractive targets for cancer drug development. In this chapter, we will present the MAPK signaling pathway and outline the function of the most relevant protein mediators that facilitate signaling. We will also highlight negative regulators of the pathway, drugs designed to block signaling, and ongoing clinical trials.


Cancer Signal transduction Oncogenes MAPK EGF Ras Raf NK ERK p38 MEK ERK RAF 


  1. 1.
    Avruch J. MAP kinase pathways: the first twenty years. Biochim Biophys Acta. 2007;1773(8):1150–60.CrossRefPubMedGoogle Scholar
  2. 2.
    Escos A, et al. p38gamma and p38delta mitogen activated protein kinases (MAPKs), new stars in the MAPK galaxy. Front Cell Dev Biol. 2016;4:31.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Dhillon AS, et al. MAP kinase signalling pathways in cancer. Oncogene. 2007;26(22):3279–90.CrossRefPubMedGoogle Scholar
  4. 4.
    Burotto M, et al. The MAPK pathway across different malignancies: a new perspective. Cancer. 2014;120(22):3446–56.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Rauch N, et al. MAPK kinase signalling dynamics regulate cell fate decisions and drug resistance. Curr Opin Struct Biol. 2016;41:151–8.CrossRefPubMedGoogle Scholar
  6. 6.
    Segal RA, Greenberg ME. Intracellular signaling pathways activated by neurotrophic factors. Annu Rev Neurosci. 1996;19:463–89.CrossRefPubMedGoogle Scholar
  7. 7.
    Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer. 2009;9(8):537–49.CrossRefPubMedGoogle Scholar
  8. 8.
    Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer. 2004;4(12):937–47.CrossRefPubMedGoogle Scholar
  9. 9.
    Yan C, Theodorescu D. RAL GTPases: biology and potential as therapeutic targets in cancer. Pharmacol Rev. 2018;70(1):1–11.CrossRefPubMedGoogle Scholar
  10. 10.
    Lal R, et al. Reovirus: rationale and clinical trial update. Curr Opin Mol Ther. 2009;11(5):532–9.PubMedGoogle Scholar
  11. 11.
    Thirukkumaran C, Morris DG. Oncolytic viral therapy using reovirus. Methods Mol Biol. 2009;542:607–34.CrossRefPubMedGoogle Scholar
  12. 12.
    Wellbrock C, Karasarides M, Marais R. The RAF proteins take centre stage. Nat Rev Mol Cell Biol. 2004;5(11):875–85.CrossRefPubMedGoogle Scholar
  13. 13.
    Forbes SA, et al. COSMIC: mining complete cancer genomes in the catalogue of somatic mutations in cancer. Nucleic Acids Res. 2011;39(Database issue):D945–50.CrossRefPubMedGoogle Scholar
  14. 14.
    Mirza AM, et al. Cooperative regulation of the cell division cycle by the protein kinases RAF and AKT. Mol Cell Biol. 2004;24(24):10868–81.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Bulavin DV, Fornace AJ Jr. p38 MAP kinase’s emerging role as a tumor suppressor. Adv Cancer Res. 2004;92:95–118.CrossRefPubMedGoogle Scholar
  16. 16.
    Cicenas J, et al. JNK, p38, ERK, and SGK1 inhibitors in cancer. Cancers (Basel). 2017; 10(1).CrossRefPubMedCentralGoogle Scholar
  17. 17.
    Cunningham SC, et al. Targeted deletion of MKK4 in cancer cells: a detrimental phenotype manifests as decreased experimental metastasis and suggests a counterweight to the evolution of tumor-suppressor loss. Cancer Res. 2006;66(11):5560–4.CrossRefPubMedGoogle Scholar
  18. 18.
    Krishnan V, et al. Using MKK4’s metastasis suppressor function to identify and dissect cancer cell-microenvironment interactions during metastatic colonization. Cancer Metastasis Rev. 2012;31(3–4):605–13.CrossRefPubMedGoogle Scholar
  19. 19.
    Zhao Y, Adjei AA. The clinical development of MEK inhibitors. Nat Rev Clin Oncol. 2014;11:385–400.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Andrei Zlobin
    • 1
  • Jeffrey C. Bloodworth
    • 2
  • Clodia Osipo
    • 3
    Email author
  1. 1.Oncology Research InstituteLoyola University Medical CenterMaywoodUSA
  2. 2.Cardinal Bernardin Cancer CenterLoyola University ChicagoMaywoodUSA
  3. 3.Department of Microbiology and ImmunologyStritch School of Medicine, Cardinal Bernardin Cancer Center of Loyola University ChicagoMaywoodUSA

Personalised recommendations